×

Order by Phone: 1 (800) 902-5523

References

CLINICAL & SCIENTIFIC PUBLICATIONS

1) Roehrborn, Claus G. “Benign Prostatic Hyperplasia: An Overview.” Reviews in Urology 7.Suppl 9 (2005): S3–S14. Print.

2) http://emedicine.medscape.com/article/437359-overview

3) Rosenberg, M.T. M. Miner, P. A. Riley and D.R. Statskin. “STEP: Simplified Treatment of the Enlarged Prostate.” Int J Clin Pract. (2010);64(4):488-496.

4) http://bestpractice.bmj.com/best-practice/monograph/172/basics/epidemiology.html

5) Talpur N1, Echard B, Bagchi D, Bagchi M, Preuss HG. Comparison of Saw Palmetto (extract and whole berry) and cernitin on prostate growth in rats. Mol Cell Biochem. 2003 Aug;250(1-2):21-6

6) Cai T et al. Serenoa repens associated with Urtica dioica and curcumin and quercitin extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomized study. Int J Antimicrob Agents 2009 Jun; 33(6): 549-53

7) Pais P. Potency of a novel saw palmetto ethanol extract, SPET-05, for inhibition of 5-alpha-reductase II. Adv Ther 2010 Aug; 27(8): 555-63

8) http://pennstatehershey.adam.com/content.aspx productId=114&pid=33&gid=000018. Accessed April 16, 2017.

9) Berges RR, Windeler J, Tramisch HJ et al. Randomized, placebo controlled clinical trial of beta sitosterol in patients with benign prostatic hyperplasia. Beta -Sitosterol Study Group. Lancet 1995:345:1529-1532

10) Klipper KF, Hiltl DM, Schipp BA. Multicentric, placebo-controlled, double blind clinical trial of beta sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia., German BPH-Phyto Study Group. BR J Urol. 1997 Sep;80(3):427-432.

11) Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms Urology 200158960–4.discussion 964–5.

12) Kravchick SG et al at the 27th Annual European Association of Urology Congress, February 24-28, 2012, Paris, France.

13) Carraro JC, JP Raynaud, G Koch, et al. Comparison of phytotherapy w (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate. 196 Octl28(4):231-40; discussion 241-2.

14) Sinescu I, Geavlete P, Multescu R, Gangu C, Miclea F, Coman I, Ioiart I, Ambert V, Constantin T, Petrut B, Feciche B, Long-Term Efficacy of Serenoa repens Treatment in Patients with Mild and Moderate Symptomatic Benign Prostatic Hyperplasia. Urol Int 2011;86:284-289

15) Ghorbanibirgani A, Khalili A, Zamani L. The Efficacy of Stinging Nettle (Urtica Dioica) in Patients with Benign Prostatic Hyperplasia: A Randomized Double-Blind Study in 100 Patients. Iran Red Cres Med J. 2013;15(1):9-10. DOI:10.5812/ircmj.2386

16) Nahata, A. and Dixit, V. K. (2012), Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats. Andrologia, 44: 396–409.

17) Pavone, C. D. Abbadessa, ML Tarantino, et al. Associating Serenoa repens, Uritca dioca and pinus pinaster. Safety and efficacynin lower urinary tract symptoms. Prospective study on 320 patients.Yrologia 2010; 77(1): 43-51.

18) Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother 2005; 5(4):1-11.

19) Lopatkin N, et al Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms--a placebo-controlled, double-blind, multicenter trial . World J Urol. (2005)

20) Bondarenko B, et al Long-term efficacy and safety of PRO 160/120 (a combination of sabal and urtica extract) in patients with lower urinary tract symptoms (LUTS). Phytomedicine. (2003)

21) Ma Z et al. Reduction of rat prostate weight by combined quercetin-finasteride treatment is associated with cell cycle deregulation. J Endocrinol 2004 Jun; 181(3): 493-507.

22) Shoskes DA et al. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. Urology 2010 Jun; 75(6): 1249-53

23) http://www.upointmd.com/index.php

24) Kim YH, Lee YJ. TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation. J Cell Biochem 2007 Mar 1; 100(4): 998-1009

25) Shoskes DA et al. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 1999; 54(6):960-63

26) Andro MC, Riffaud JP. Pygeum africanun extract for treatment of patients with BPH: a review of 25 years of published experience. Curr Ther Res. 1995;56:796-817.

27) Carani C, Salvioli V, Scuteri A, et al. Urological and sexual evaluation of treatment of benign prostatic disease using Pygeum africanum at high doses. Arch Ital Urol Nefrol Androl. 1991 Sep;63(3):341-5

28) Chatelain C et al. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology 1999 Sep; 54(3):473-78.

29) Barlet A et al. Efficacy of Pygeum africanum extract in the treatment of micturational disorders due to benign prostatic hyperplasia. Evaluation of objective and subjective parameters. A multicenter, randomized, double-blind trial. Wein Klin Wochenschr 1990;102:667–73.

30) Breza J et al. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. Curr Med Res Opin 1998; 14(3):127-39.

31) Yablonsky FP et al. Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts. J Urol 1997; 157:2381-87.

32) Levin RM, Riffaud JP, Bellamy F, et al. Effects of Tadenan pretreatment on bladder physiology and biochemistry following partial outlet obstruction. J Urol. 1996;156:2084-2088.

33) D Boulbès et al. Pygeum Africanum Extract Inhibits Proliferation of Human Cultured Prostatic Fibroblasts and Myofibroblasts. BJU Int 98 (5), 1106-1113. 11 2006.

44) MT Quiles et al. Antiproliferative and Apoptotic Effects of the Herbal Agent Pygeum Africanum on Cultured Prostate Stromal Cells From Patients With Benign Prostatic Hyperplasia (BPH) . Prostate 70 (10), 1044-1053. 2010 Jul 01.

34) http://www.umm.edu/health/medical/altmed/condition/benign-prostatic-hyperplasia. Accessed April 14, 2017

48) Andro MC, Riffaud JP. Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: a review of 25 years of published experience. Curr Ther Res 1995;56:796-817.

35) Monograph. Pygeum africanum. Alternative Medicine Review. V7(1).2002

36) Alschuler L. Grean Tea: Healing tonic. Am J Natur Med 1998;5:28-31.

37) Graham HN. Green tea composition, consumption, and polyphenol chemistry. Prev Med 1992;21:334-350.

38) Gupta S, Hastak K, Ahmad N, et al.: Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A 98 (18): 10350-5, 2001.

39) Obermüller-Jevic UC, Olano-Martin E, Corbacho AM, et al.: Lycopene inhibits the growth of normal human prostate epithelial cells in vitro. J Nutr 133 (11): 3356-60, 2003.

40) Yang CM, Lu IH, Chen HY, et al.: Lycopene inhibits the proliferation of androgen-dependent human prostate tumor cells through activation of PPARγ-LXRα-ABCA1 pathway. J Nutr Biochem 23 (1): 8-17, 2012.

41) Zhang X, Wang Q, Neil B, et al.: Effect of lycopene on androgen receptor and prostate-specific antigen velocity. Chin Med J (Engl) 123 (16): 2231-6, 2010.

42) Yang CM, Yen YT, Huang CS, et al.: Growth inhibitory efficacy of lycopene and β-carotene against androgen-independent prostate tumor cells xenografted in nude mice. Mol Nutr Food Res 55 (4): 606-12, 2011.

43) Schwarz S , U Obermueller-Jevic, E Hellmis, et al. Lycopene inhibits disease progression in patients with Benign prostate hyperplasia. 139(1) 49-53.

44)/ Mohanty NK, S Saxena, UP Singh, et al. Lycopene as a chemopreventive agent in the treatment of high grade prostate intraepithelial neoplasma. Urol Oncol. 2005 Nov-Dec;23(6):383-5.

45) Zhang W, Joseph E, Hitchcock C, et al.: Selenium glycinate supplementation increases blood glutathione peroxidase activities and decreases prostate-specific antigen readings in middle-aged US men. Nutr Res 31 (2): 165-8, 2011.

46) Adorini L, Penna G, Fibbi B, et al. Vitamin D receptor agonists target static, dynamic, and inflammatory components of bening prostatic hyperplasia. Ann NY Acad Sci. 2010 Apr;1193:146-152. Review.

47) Prasad AS, Beck FW, Bao B, et al. Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress. Am J Clin Nutr. 2007 Mar;85(3):837-44.

48) Netter A, R Hartoma, K Nahoul. Effect of zinc administration on plasma testosterone, dihydrotestosterone and sperm count. Arch Androl. 1981, Aug;7(1):69-73.

49) https://www.ncbi.nlm.nih.gov/books/NBK222317/#ddd00590. Accessed Apr 16 2017.

50) Suter, Andreas, R Saller, et al. Improving BPH symptoms and sexual dysfunctions with saw palmetto preparation. Results from a pilot trial. Phytother. Res. Feb 2013.

51) Ghorbanibirgani, Alireza, Ali Khalili, and Laleh Zamani. “The Efficacy of Stinging Nettle (Urtica Dioica) in Patients with Benign Prostatic Hyperplasia: A Randomized Double-Blind Study in 100 Patients.” Iranian Red Crescent Medical Journal 15.1 (2013): 9–10. PMC. Web. 18 Apr. 2017.